Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India

Mumbai & Bangalore, India: June 2, 2015 - Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and AstraZeneca Pharma India Limited (AZPIL) (BSE : 506820, NSE : ASTRAZEN, AZPIL) today announced that AZPIL and  Sun Pharma have entered into a distribution services agreement in India for AstraZeneca's brand "Axcer®", a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS) . AZPIL already has a brand under the trademark "Brilinta®", for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. 

Abhay Gandhi, CEO - India Business, Sun Pharma said, "We are happy to collaborate with AstraZeneca to provide customers access to this latest generation treatment option for ACS. Such collaborations are also a part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country." 

Sanjay Murdeshwar, Managing Director, AstraZeneca Pharma India Limited said, "We are pleased to collaborate with Sun Pharmaceuticals to bring this innovative treatment solution to a larger number of ACS patients in India. Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death." 

Sun Pharma will be promoting and distributing "Axcer®" brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy. 


About Ticagrelor 

Ticagrelor is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor works by inhibiting platelet activation.Ticagrelor (90mg) is indicated to reduce the rate of thrombotic CV events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). Ticagrelor has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis. 

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050): 

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 45 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 12 different classes of doctors with 31 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 50 countries and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 11 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 1800 scientists and R&D investments of over 7% of annual revenues. For further information please visit 

About AstraZeneca 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit 

You have received this email as your address is part of our Investor Relations and Media Contacts list.  All our Press Releases and Financial updates are sent to those on the list. 
•        If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it.   
       All the others will continue to be on the mailing list. 
•        If you wish to receive emails on some other email id, please send it to us. 
•        If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add. 
•        If you are changing jobs, please send us your new email id.  We would like to be in touch with you and keep you updated on happenings at Sun Pharma. 

We would be happy to host one-on-one, group and telephone meetings for updates on the Company.  If you wish to setup such a meeting, feel free to get in touch with us.  In-person meetings can be at our office or elsewhere depending on mutual convenience.  Our contact details: 

Sun Pharma:
Nimish Desai 
Tel : +91 22 4324 4324, Ext 2778 
Tel Direct : +91 22 43242778 
Mobile : +91 98203 30182 
E mail: [email protected]
Frederick Castro 
Tel : +91 22 4324 4324, Ext 2777 
Tel Direct : +91 22 43242777 
Mobile : +91 99206 65176 
E mail : [email protected]

AstraZeneca Pharma India:
Varsha Das
Tel : +91 80.67748497
Mobile : +91. 9741752900
E mail: 
[email protected]